No black box warning on record for Spinraza

As of the latest FDA labeling reviewed, Spinraza (NUSINERSEN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Spinraza medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Thrombocytopenia and Coagulation Abnormalities: Increased risk for bleeding complications; testing required at baseline and before each dose and as clinically needed ( 5.1 , 2.3 ) Renal Toxicity: Quantitative spot urine protein testing required at baseline and prior to each dose ( 5.2 , 2.3 ) 5.1 Thrombocytopenia and Coagulation Abnormalities Coagulation abnormalities an

No black box warning on record for Spinraza

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Thrombocytopenia and Coagulation Abnormalities: Increased risk for bleeding complications; testing required at baseline and before each dose and as clinically needed ( 5.1 , 2.3 ) Renal Toxicity: Quantitative spot urine protein testing required at baseline and prior to each dose ( 5.2 , 2.3 ) 5.1 Thrombocytopenia and Coagulation Abnormalities Coagulation abnormalities an

Spinraza Black Box Warning

No black box warning on record for Spinraza

Other warnings & precautions

Spinraza Black Box Warning

No black box warning on record for Spinraza

Other warnings & precautions